Journal
Blood Advances
Publication Date
10-25-2022
Volume
6
Issue
20
First Page
5634
Last Page
5640
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2022007705
Rights and Permissions
Ghobadi A, Landmann JH, Carter A, Cooper ML, Selli ME, Chang J, Baker M, Miller CA, Ferraro F, Chen DY, Smith AM, LaValle TA, Duncavage EJ, Chou J, Tam V, Benoun JM, Nater J, Scholler N, Milletti F, Vezan R, Bot A, Rossi JM, Singh N. Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies. Blood Adv. 2022 Oct 25;6(20):5634-5640. doi: 10.1182/bloodadvances.2022007705. © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Ghobadi, Armin; Landmann, Jack H; Carter, Alun; Cooper, Matthew L; Selli, Mehmet Emrah; Chang, Jufang; Miller, Christopher A; Ferraro, Francesca; Chen, David Y; Smith, Amanda M; LaValle, Taylor A; Duncavage, Eric J; Singh, Nathan; and et al., "Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies." Blood Advances. 6, 20. 5634 - 5640. (2022).
https://digitalcommons.wustl.edu/oa_4/1380
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
